Bluejay Diagnostics IncNASDAQ BJDX Stock Report

Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts. The company went IPO on 2021-11-10. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. Symphony platform is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. The firm is developing a pipeline of diagnostic tests for Symphony, including triage of myocardial infarction (MI), congestive heart failure (CHF), neutropenic sepsis in cancer, and other disease diagnostic indications using the same Symphony platform. The firm's Symphony IL-6 product candidate is for early and rapid identification of sepsis during Emergency Department (ED), critical care triage, and neutropenic sepsis in oncology patients. Symphony IL-6 product candidate is also for monitoring disease progression during such treatment regimen.